Background-Transforming growth factor beta-1 (TGFβ 1 ) is thought to play a role in airway remodeling in asthma. TGFβ 1 expression may be mediated by an excessive burden of reactive oxygen species and oxidant stress.
INTRODUCTION
Severe asthma in children is a complicated disorder encompassing children with both difficult-to-treat asthma and severe, refractory asthma 1 that is characterized by poor symptom control despite best attempts at treatment with high doses of inhaled corticosteroids (ICS) and other asthma controller medications. [2] [3] [4] The symptoms that accompany severe asthma in children are further associated with marked deficits of pulmonary function, including airflow limitation, that are not completely reversible with bronchodilator therapy and worsen significantly over time. 5, 6 Although the specific mechanisms underlying pulmonary function derangements in children with severe asthma are yet unclear, structural changes in the airway wall (i.e., "remodeling") are likely responsible. 7, 8 Transforming growth factor beta 1 (TGFβ 1 ) is a pro-fibrotic cytokine that is associated with airway fibrosis. 9 TGFβ 1 is synthesized as a pre-propeptide precursor and is secreted as an inactive heterodimer bound to a latent complex that is targeted to TGFβ 1 binding proteins within the extracellular matrix. While there are several molecular mechanisms involved in the activation of TGFβ 1 , exposure to reactive oxygen species has been shown to induce rapid cleavage of TGFβ 1 from the latent complex, presumably through alteration of the latent associated protein. 10 Once TGFβ 1 is cleaved to the active (free) form, it binds to TGFβ 1 receptors on target cells in the extracellular matrix. While this process is essential for airway wound repair and healing, sustained activation of TGFβ 1 inhibits beneficial TGFβ 1 signaling 11 and also activates fibroblasts and the epithelial-mesenchymal trophic unit, resulting in further release of reactive oxygen species and ultimately airway remodeling. 12, 13 The end result is a vicious cycle of oxidant stress whereby TGFβ 1 is chronically activated.
Although airway oxidant stress is a prominent feature of severe asthma in children, the relationship of oxidant stress and TGFβ 1 in this population has not been described. Compared to children with mild-to-moderate asthma, children with severe asthma have marked depletion of the airway antioxidant, glutathione, which corresponds to the magnitude of airflow limitation. 14, 15 This disturbance is associated with increased formation of lipid peroxidation byproducts (8-isoprostanes and malondialdehyde), 15 greater DNA nucleoside 14 and nitric oxide 16 oxidation, and sustained expression of proinflammatory cytokines and chemokines. 17 Whereas key transcription factors such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2) should stimulate glutathione and antioxidant defenses under these circumstances, Nrf2 is not active in these children and thus the oxidant burden is intensified. 18 While the mechanisms underlying these observations remain poorly understood, TGFβ was recently shown to inactivate Nrf2 in airway smooth muscle cells from subjects with severe asthma. 19 Thus TGFβ 1 may be a key mediator of the airway oxidant burden in severe asthmatic children. Given the relative paucity of pediatric severe asthma bronchoscopy studies and the magnitude of symptoms in this population, we sought to: 1) quantify TGFβ 1 protein and mRNA gene expression in the airways of children with mild-to-moderate and severe atopic asthma, and 2) determine the relationship of airway TGFβ 1 concentrations to oxidant burden (i.e., lipid peroxidation), Th2-mediated eosinophilic inflammation, and airflow limitation. We hypothesized that TGFβ 1 expression and activation would be increased in children with severe asthma and would be associated with increased 8-isoprostane, malondialdehyde and IL-13 concentrations, increased exhaled nitric oxide concentrations, and a greater magnitude of airflow limitation.
METHODS

Subjects
Recruitment was limited to children 6-18 years of age with physician-diagnosed atopic asthma and atopic adults. All subjects were sensitized to at least one aeroallergen, or alternatively, had physician-diagnosed allergic rhinitis, atopic dermatitis, or evidence of at least 12% reversibility in the forced expiratory volume in one second (FEV 1 ) and stable prescribed ICS therapy for at least six weeks. Children with immunodeficiency, cystic fibrosis, chronic aspiration syndromes, and birth prior to 35 weeks gestation were excluded. Additional inclusion criteria for atopic adults included normal spirometric indices without bronchodilator reversibility, no history of smoking or lung disorders and no upper respiratory illness within 4 weeks. Severe asthma was diagnosed according to American Thoracic Society criteria, 20 with thresholds for high-dose ICS defined as ≥ 440 mcg of fluticasone equivalent per day for children less than 12 years and ≥ 880 mcg per day for children 12-18 years of age. Informed consent and assent were obtained from all participating adults and children, respectively. Caregivers of participating children also provided informed consent.
Characterization procedures
Spirometry was performed in the outpatient setting with a portable spirometer (KoKo® Legend, Ferraris, Louisville, CO) at baseline and after 4 inhalations of albuterol sulfate through a metered dose inhaler. The best of three forced vital capacity (FVC) maneuvers was interpreted. 21 Exhaled nitric oxide concentrations were quantified using online methods (NIOX MINO®, Aerocrine Inc., New Providence, NJ) with a fixed flow rate of 0.05 L/ second and exhalation duration of 6 seconds. Venipuncture was performed immediately prior to bronchoscopy for determination of plasma urea. Serum IgE levels were determined by a commercial laboratory (Quest Diagnostics, Tucker, GA).
Bronchoscopy and sample processing
Children underwent bronchoscopy with bronchoalveolar lavage (BAL) for clinical indications, namely persistent asthma symptoms despite best attempts at ICS treatment (Online repository Table E1 ). Adult volunteers underwent bronchoscopy for research purposes. All subjects were clinically stable at the time of bronchoscopy with no evidence of an acute upper respiratory tract infection, including no rhinorrhea and no increase in chest symptoms or short-acting bronchodilator use for two weeks prior to the procedure. Pediatric bronchoscopy was performed under general anesthesia using a laryngeal mask airway and flexible bronchoscope (Olympus BF-3C160, Olympus America Inc., Melville, NY). BAL fluid was collected from the right middle lobe with three 1 mL/kg (50 mL maximum) saline lavages. Adults received conscious sedation, during which a flexible bronchoscope (Olympus BF-1T20D) was passed trans-nasally into the right middle lobe. Three 50 mL saline aliquots were instilled. For children, the BAL fluid was pooled and divided between the research and clinical laboratories. BAL samples were centrifuged at 1200 rpm for 7 minutes immediately after collection. Cellular differentials were determined from 300 consecutive cells after Wright staining. Airway macrophages were further purified from the cell pellet by adherence to plastic. Cytospins were made and the resulting cells were preserved for TGFβ 1 analysis or added to 5 volumes of RNAlater® for RNA extraction (Applied Biosciences, Carlsbad, CA). Urea nitrogen was measured in plasma and BAL supernatant using a quantitative colorimetric assay (Pointe Scientific, Canton, MI) with sensitivity of 0.05 to 150 mg/dL. 
TGFβ 1 expression
TGFβ 1 concentrations in the BAL supernatant were quantified using a commercial ELISA (Promega, Madison, WI) that detects the active form and has ≤3% cross-reactivity with other TGFβ isoforms. Total (latent + active) TGFβ 1 concentrations in the BAL supernatant and airway macrophage lysate were determined after treatment with hydrochloric acid and neutralization with sodium hydroxide. Data were analyzed at an absorbance of 450 nm. Airway macrophage TGFβ 1 concentrations were normalized to the cellular protein content, which was determined using a Coomassie protein assay (Pierce Biotechnology, Rockford, IL). TGFβ 1 protein expression was further analyzed by fluorescent microscopy in airway macrophage cytospins using an anti-rabbit TGFβ 1 antibody (sc-31609, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Relative fluorescent units of TGFβ 1 were assessed by quantitative digital analysis from 10 experimental fields per set using Image-Pro Plus for Windows (Version 3.1, Media Cybernetics, Inc., Silver Spring, MD).
TGFβ 1 mRNA gene expression in airway macrophages was determined after isolation of RNA using a commercial kit (RNeasy Mini, Qiagen, Valencia, CA). 10 ng of total RNA per sample was reverse transcribed using MultiScribe® Reverse Transcriptase (62.U/50 µL reaction), RNase Inhibitor, oligoT primers and MgCl 2 at a concentration of 5.5 mM (Applied Biosystems, Carlsbad, CA). cDNA aliquots were used to quantify relative levels of TGFβ 1 (TGFB1, Hs645227) in a 96-well assay system (StepOnePlus real-time PCR assay; Applied Biosystems, Carlsbad, CA) with TaqMan primer pairs and probes (Applied Biosystems, Carlsbad, CA). Data were normalized to the β2 microglobulin housekeeping gene (B2M, Hs534255). Net cycle threshold (CT) values were used to calculate ΔCT values for each subject, using the average CT of housekeeping gene as a reference.
Inflammatory and oxidative biomarkers
IL-13 was measured in the BAL supernatant using a bead-based assay with a sensitivity of 0.3 pg/mL (Millipore, Billerica, MA) analyzed on BioRad Bio-Plex System (Bio-Rad Laboratories, Hercules, CA) with gates of 4335 and 10,000. 8-isoprostane concentrations in the BAL supernatant were quantified by a commercial ELISA (Cayman Chemical, Ann Arbor, MI) with a detection limit of 2.7 pg/mL measured at an absorbance at 420 nm. Malondialdehyde concentrations were determined in the BAL supernatant with a spectrophotometric assay (Bioxytech® MDA-586, Oxis International, Foster City, CA) with a detection limit A 586 of 0.0088 at 586 nm absorbance.
Data analysis
Data analysis was performed with SPSS® software (Version 19, SPSS Inc., Chicago, IL). TGFβ 1 , IL-13, 8-isoprostane and malondialdehyde concentrations were expressed per mL of BAL and were also adjusted according to the urea dilution to yield values per mL of epithelial lining fluid (ELF). TGFβ 1 , IL-13, 8-isoprostane and malondialdehyde concentrations were not normally distributed and were logarithmically transformed with a natural logarithm function (i.e., ln(e)) prior to statistical analyses. Airway macrophage TGFβ 1 concentrations were expressed per ng of protein. mRNA gene expression was analyzed relative to the atopic adult control group and expressed as 2 −ΔΔCT values. Airflow limitation was defined as an FEV 1 < 80% predicted or FEV 1 /FVC < 0.85. Differences between groups were assessed by chi-square and Kruskal-Wallis tests of significance, Mann-Whitney U tests were used for post-hoc testing, with significance defined as α < 0.05. Bivariate Pearson correlations were used to examine associations between linear variables. Logistic regression analyses were performed with airflow limitation as the dependent variable and asthma characteristics and TGFβ 1 concentrations as predictors. Univariate regression models (including each of the baseline measures) were first used to narrow the list of covariates (statistically significant at p < 0.05) to be incorporated in the final multivariate model.
RESULTS
Sixty-eight children with atopic asthma (severe asthma, n = 28) and 12 atopic adult controls were recruited. Indications for bronchoscopy in children are shown in the online repository (Table E1) . Bronchoscopy was well tolerated in all subjects with no adverse events. Features of the groups appear in Table I . Within the mild-to-moderate group, 19 had mild asthma treated with low doses of inhaled corticosteroids (≤ 220 mcg inhaled fluticasone/day for age <12 years; ≤ 440 mcg of inhaled fluticasone/day for age ≥12 years). Children with severe asthma, by definition, were prescribed higher doses of ICS and additional controller medications but had greater healthcare utilization for asthma in the preceding year. Children with severe asthma also had higher exhaled nitric oxide concentrations and increased airway lavage eosinophils that corresponded to elevations of total serum IgE (control: 144 ± 61 kU/ L; mild-to-moderate: 123 ± 33 kU/L; severe: 549 ± 143 kU/L, p < 0.001). Airflow limitation both at baseline and after bronchodilation were also features of the severe asthma group. However, at the same time, more children with severe asthma had FEV 1 bronchodilator reversibility >12% compared to children with mild-to-moderate asthma (57% vs. 16%, p = 0.001), most likely due to a higher baseline FEV 1 percent predicted value in the mild-tomoderate group. Other features of the airway lavage such as the protein and urea content did not differ (control vs. mild-to227 moderate vs. severe, protein: 134 ± 84 vs. 177 ± 116 vs. 187 ± 74 µg/mL, p = 0.144; urea: 0.57 ± 0.41 vs. 0.51 ± 0.48 vs. 0.40 ± 0.59 mg/dL, p = 0.104).
Airway lavage TGFβ 1 concentrations
Total (latent + active) airway TGFβ 1 concentrations in the BAL supernatant did not differ between atopic adult controls and children with mild-to-moderate asthma ( Figure 1A ). However, total BAL TGFβ 1 concentrations were significantly higher in children with severe asthma and were associated with higher concentrations of active (free) TGFβ 1 ( Figure 1B) . Similar findings were also observed in the ELF after normalization of the BAL for urea ( Figure 1C, 1D) . In the combined sample of children with mild-to-moderate and severe asthma, total and active (free) BAL TGFβ 1 concentrations were not significantly associated with age, ICS dose, exhaled nitric oxide concentration, serum IgE concentration, or airway eosinophils or neutrophils (Online repository Table E2 ). However, total airway TGFβ 1 concentrations in the BAL supernatant were modestly correlated with baseline measures of airflow limitation in the combined group of asthmatic children (Online repository Table  E3 ).
Airway macrophage TGFβ 1 expression
Airway macrophages were a significant source of airway TGFβ 1 production in children with severe asthma. Compared to controls and children with mild-to-moderate asthma, children with severe asthma had higher concentrations of total TGFβ 1 in the airway macrophage lysate (Figure 2A ). Increased protein expression of TGFβ 1 in the airway macrophages of children wit h severe asthma was also confirmed by direct immunofluorescence ( Figure 2B ) and was accompanied by increased airway macrophage mRNA expression of TGFβ 1 ( Figure  2C ). Airway macrophage TGFβ 1 concentrations were further correlated with total and active (free) TGFβ 1 concentrations in the BAL supernatant and ELF (Online repository Table  E1 ).
BAL supernatant IL-13, 8-isoprostane and malondialdehyde concentrations
IL-13, 8-isoprostane and malondialdehyde concentrations were elevated in the BAL supernatant and ELF of both groups of asthmatics as compared to controls (Figure 3) . Although IL-13 and 8-isoprostane concentrations did not consistently differentiate asthma severity groups, malondialdehyde concentrations increased as a function of asthma severity and were highest in children with severe asthma (Figure 3C, 3F) . In the combined sample of children with mild-to-moderate and severe asthma, 8-isoprostane and malondialdehyde concentrations correlated with total TGFβ 1 concentrations in the BAL supernatant and ELF, however, no associations between TGFβ 1 and IL-13 were observed (Figure 4 
Associations between TGFβ 1 and airflow limitation
To test the association between airway TGFβ 1 concentrations and airflow limitation, univariate logistic regression analyses were first performed with baseline (prebronchodilator) airflow limitation as the dependent variable and asthma characteristics as predictors. These analyses were restricted to children with mild-to-moderate and severe asthma a nd did not include the atopic adult controls. Using this approach, race, systemic corticosteroid use, an emergency asthma visit within the preceding year, hospitalization for asthma within the previous year and baseline exhaled nitric oxide concentrations were significant predictors of airflow limitation in children with mild-to-moderate and severe asthma (Table II) . Airway IL-13, 8-isoprostane and malondialdehyde concentrations were not associated with airflow limitation in this sample (data not shown). However, total TGFβ 1 concentrations in both the BAL and airway macrophage lysate were associated with airflow limitation (Table II) . Of the significant baseline asthma characteristics, race, exhaled nitric oxide concentrations, and total BAL TGFβ 1 concentrations remained associated with airflow limitation in children with asthma in the multivariable model after controlling for the other significant variables ( Table  E6 ). However, there was a lack of precision in the resulting estimates in both multivariable models of airflow limitation due to limited sample sizes.
DISCUSSION
To our knowledge, this is the first study to comprehensively assess airway TGFβ 1 expression and activation and the relationship of airway TGFβ 1 to Th2-mediated inflammation, oxidant stress and functional assessments of airway remodeling in a heterogeneous sample of children with atopic asthma. A unique strength of the study is the inclusion of children with severe asthma, who, when compared to children w ith mild-tomoderate asthma and atopic adult controls, had higher airway TGFβ 1 concentrations and increased protein and gene expression of TGFβ 1 in airway macrophages. Moreover, the airway oxidative burden reflected by the lipid peroxidation biomarkers 8-isoprostanes and malondialdehyde was also greater in children with severe asthma and was associated with increased TGFβ 1 cleavage and activation. Furthermore, within the combined sample of children with mild-to-moderate and severe atopic asthma, airway TGFβ 1 concentrations were associated with airflow limitation. Together, these data suggest that increased expression and activation of airway TGFβ 1 , along with an increased airway oxidant burden, may underlie the airway physiological alterations that accompany severe asthma in children.
TGFβ 1 is a pleiotropic cytokine that is widely expressed by airway cells and is thought to play a key role in airway remodeling in asthma. 9 While increased TGFβ 1 protein and mRNA gene expression have been previously described in the airways of asthmatic adults at baseline and after segmental allergen challenge, [23] [24] [25] [26] [27] airway TGFβ 1 expression and activation have not been well quantified in children and no studies to date have focused on children with severe asthma. In two recent studies of predominantly mild asthmatic children who underwent endobronchial biopsy for clinical indications, no qualitative differences in the number of TGFβ 1 -expressing subepithelial cells were noted as compared to controls. 28, 29 Thus it was concluded that TGFβ 1 may be downregulated in childhood asthma. 29 While we also failed to observe differences in TGFβ 1 expression between mild-tomoderate asthmatic children and atopic adults, our finding of increased TGFβ 1 protein and mRNA gene expression in children with severe asthma refutes this claim. Moreover, we observed increased cleavage and activation of TGFβ 1 in children with severe asthma associated with a significant (i.e., 2-fold) increase in the lipid peroxidation biomarkers 8-isoprostanes and malondialdehyde. While the causal relationship between TGFβ 1 and lipid peroxidation i s not clear, the 8-isoprostane and malondialdehyde concentrations observed here are similar to what we have previously reported in this population. [14] [15] [16] Although additional studies are needed, these findings support previous findings of TGFβ 1 -mediated inactivation of Nrf2 19 and suggest that an ongoing cycle of TGFβ 1 activation from sustained generation of reactive oxygen species may underlie irreversible airway injury and remodeling in these children.
While the airway epithelium is the predominant site of airway TGFβ 1 expression in the lung, 30 other cells such as fibroblasts 31 and airway smooth muscle cells 32 also contribute to airway TGFβ 1 pools in asthmatic subjects. In the present study, although airway epithelial cells were not available for analysis, we observed increased TGFβ 1 protein and mRNA expression in airway macrophages from children with severe asthma similar to previous findings in asthmatic adults. 33 These observations are also in keeping with our previous observations of increased airway macrophage activation and pro-inflammatory cytokine release in this population of children. 17 In the present study, we did not observe a clear association between TGFβ 1 expression and airway lavage eosinophils in our sample of asthmatic children. However, others have shown that the number of airway lavage eosinophils does not necessarily correlate with mucosal eosinophilia in children with severe asthma. 34 While airway eosinophils are known to be a significant source of TGFβ 1 in patients with asthma, 24 insufficient eosinophils counts in the present study prohibited isolation of these cells and thus their specific contribution to airway TGFβ 1 pools is unclear. However, the role of the eosinophil in these findings warrants further study. In previous investigations involving both animals 35 and humans, 36 inhibition of IL-5, a key mediator of eosinophil activation, attenuated TGFβ 1 expression and subsequent airway remodeling.
We also failed to observe significant associations between airway TGFβ 1 and exhaled nitric oxide concentrations. This is in contrast to previous work by Mahut et al. which demonstrated correlations between alveolar nitric oxide and BAL TGFβ 1 concentrations in asthmatic children. 37 However, that study did note a strong association between maximal conducting exhaled nitric oxide output and reticular basement membrane thickening. 37 Although the clinical relevance of reticular basement membrane thickening remains controversial, 38 reticular basement membrane thickness has been associated with airflow limitation in children with asthma 7, 8 and therefore supports our observed associations between exhaled nitric oxide and airflow limitation in this sample.
Because increased TGFβ 1 is associated with allergic sensitization independent of asthma, 39 all of the subjects included in this study were atopic. While the inclusion of atopic subjects was important for our TGFβ 1 analyses, the exclusion of non-atopic subjects may have decreased the variability in our other measures. For instance, although airway lavage eosinophils and IL-13 concentrations were increased in both groups of asthmatic children, they did not differentiate asthma severity. Given that IL-13 has been shown to induce TGFβ 1 expression, 40 our observation of increased IL-13 in children with mild-to-moderate asthma may appear counterintuitive since TGFβ 1 expression was not significantly different in this group. However, we did observe correlations between IL-13 and free TGFβ 1 concentrations in the ELF, suggesting that IL-13 may be more relevant to the process of TGFβ 1 activation. Furthermore, TGFβ 1 and IL-13 are also synergistic 41 and thus TGFβ 1 is essential for IL-13-mediated airway remodeling and fibrosis. 13 This synergism between IL-13 and TGFβ 1 likely explains why airflow limitation was less pronounced in our sample of children with mild-to-moderate asthma despite higher expression of IL-13 in the airways.
While severe asthma in children is clearly a heterogeneous condition associated with a number of clinical phenotypes, 4 airflow limitation is common feature of the disorder that is identifiable during early childhood. 2, 3 Although airflow limitation is less pronounced in children as compared to adults with severe asthma, it persists across the lifespan and declines further as a function of the normal aging process. 42 A subset of children with severe asthma also experiences a rapid worsening of airflow limitation during the early adolescent years 5 which further increases the risk of severe, life-threatening asthma exacerbations and other adverse outcomes. 43 While the mechanisms underlying the progression of airflow limitation in children with severe asthma are not clear, our findings suggest that TGFβ 1 may play a role in this process. Importantly, airway TGFβ 1 expression in children with severe asthma was increased to a similar magnitude as what has been previously reported in severe asthmatic adults. 25 Furthermore, in this cross-sectional sample, airway TGFβ 1 concentrations were associated with airflow limitation, even after controlling other relevant factors. However, whether airway TGFβ 1 concentrations predict loss of lung function over time is unclear and warrants further study. This study does have a number of limitations. Because bronchoscopy could only be performed for clinical indications in children, our control group was limited to atopic adults. Whether there are developmental differences in airway TGFβ 1 expression between adults and children is not clear. Also the utilization of clinical bronchoscopy samples from children resulted in relatively small group sizes wherein a number of comparisons were made, potentially increasing the risk of Type I statistical error. Utilization of clinical bronchoscopy samples also prohibited the collection of endobronchial biopsies for histological analysis and the isolation of other cell types, such as airway eosinophils and fibroblasts, which are important sources of TGFβ 1 . 9, 24 While it is also unclear how asthma medications may have affected the results, comparisons between children with severe and mild-to-moderate asthma help to eliminate potential confounding by asthma medication exposure and other key variables in the medical history. Although all children in this study were prescribed treatment with ICS, another potential shortcoming is related to adherence with ICS therapy since adherence was not rigorously assessed. The striking racial disparity between our asthmatic groups is also a potential source of confounding that warrants additional investigation. However, despite the relationship between race and airflow limitation that we observed here, we failed to observe consistent associations between race and airway TGFβ 1 expression (Online repository Figure E2 ).
In summary, we have demonstrated increased TGFβ 1 protein and mRNA gene expression in the airways of children with severe asthma associated with increased concentrations of the lipid peroxidation biomarkers 8-isoprostanes and MDA. Contrary to our hypothesis, we failed to observe consistent associations between airway TGFβ 1 and Th2-mediated eosinophilic inflammation and exhaled nitric oxide. However, TGFβ 1 activation as measured by free TGFβ 1 did correlate with concentrations of IL-13 in the ELF. While the mechanisms underlying these observations are not clear, these findings suggest an altered feedback mechanism in the airways of children with severe asthma resulting in a vicious cycle of airway oxidant stress and persistent TGFβ 1 activation. Given that TGFβ 1 concentrations were associated with airflow limitation in this sample of asthmatic children, additional studies are now warranted to determine how TGFβ 1 modulates longitudinal derangements of lung function and other outcomes in asthmatic children. Ultimately, interventions to attenuate TGFβ 1 expression and activation may be warranted in children with severe asthma to the structural airway changes and resulting symptoms associated with the disorder. Total and active (free) TGFβ 1 concentrations in the BAL supernatant (panels A and B, respectively) and ELF (panels C and D, respectively) of atopic adult controls (AC), children with mild-to-moderate atopic asthma (MMA) and children with severe atopic asthma (SA). Horizontal lines represent the median. P-values were obtained after natural logarithmic transformation. Concentrations of IL-13, 8-isoprostanes and malondialdehyde (MDA) in the BAL (panels A-C, respectively) and ELF (panels D-F, respectively) of atopic adult controls (AC), children with mild-to-moderate atopic asthma (MMA) and children with severe atopic asthma (SA). IL-13 concentrations were undetectable in 8 atopic adult controls. Horizontal lines represent the median. P-values were obtained after natural logarithmic transformation. Scatterplots with regression lines depicting the relationship between total TGFβ 1 and IL-13, 8-isoprostane, and MDA concentrations in the BAL supernatant (panels A-C) and ELF (panels D-F) of children with mild-to-moderate and severe asthma. 
